Plasma Copeptin as a Prognostic Marker in Children with Heart Failure

Area of Science:

• Pediatric Cardiology
• Biomarker Research
• Critical Care Medicine

Background:

• Heart failure (HF) in children presents significant mortality and morbidity risks.
• Early identification of high-risk pediatric HF patients is crucial for timely intervention.
• Novel biomarkers are needed to improve risk stratification in pediatric HF.

Purpose of the Study:

• To evaluate plasma copeptin as a predictor of mortality in pediatric heart failure (HF).
• To assess the association of plasma copeptin with poor outcomes such as sepsis, multiorgan dysfunction syndrome (MODS), and mechanical ventilation requirement.
• To determine the correlation between plasma copeptin levels and pediatric intensive care unit (PICU) stay duration.

Main Methods:

• A diagnostic study involving 76 children (1 month-16 years) with HF due to congenital or acquired heart disease.
• Comparison with 65 age- and gender-matched healthy children.
• Plasma copeptin levels measured within 24 hours of admission; HF patients stratified into quartiles based on copeptin levels.

Main Results:

• Children with HF exhibited significantly higher median plasma copeptin levels (16.8 pmol/L) than healthy controls (8.0 pmol/L).
• Higher copeptin quartiles correlated with increased Pediatric Risk of Mortality III (PRISM III) and inotropic scores.
• Increased incidence of sepsis, MODS, and mechanical ventilation was observed in the highest copeptin quartile (Q4).
• A plasma copeptin level of 35.5 pmol/L demonstrated 72% sensitivity and 92.5% specificity for predicting mortality in pediatric HF.

Conclusions:

• Plasma copeptin serves as a valuable novel biomarker for early mortality prediction in pediatric heart failure.
• Elevated plasma copeptin levels are associated with increased severity and adverse outcomes in children with HF.
• Copeptin may aid in identifying children with HF at high risk for poor prognosis, guiding clinical management.